Novo Nordisk (NVO.N) stated that in clinical trials, the company's cangrisema failed to meet the efficacy criteria of being non-inferior to Eli Lilly's tirzepatide.
2026-02-23
Novo Nordisk (NVO.N) stated that in clinical trials, the company's cangrisema failed to meet the efficacy criteria of being non-inferior to Eli Lilly's tirzepatide.